- Company
- Wet AMD tx new option to shorten Eyelea's minimum cycle
- by May 16, 2022 06:13am
- Bayer's macular degeneration treatment Eyelea took the lead in establishing an optimized treatment strategy for patients by shortening the minimum treatment cycle. It is evaluated that a new option was presented in macular degeneration treatment that determines the treatment cycle according to the patient's condition. According to the phar
- Company
- Bio Clusters gather to compete at BIO Korea 2022
- by Kim, Jin-Gu May 13, 2022 05:46am
- Major Bio Clusters of local governments have gathered in one place. Major Bio Clusters of local governments including Osong, Incheon, Hongneung, Gimhae, Wonju, and Daejeon municipalities as well as the event’s co-host Chungcheongbuk-do are in heated competition to promote their cluster in the ‘BIO KOREA 2022’ event that is being held f
- Policy
- MOHW holds a launching meeting of the pharmaceutical team
- by Kim, Jung-Ju May 13, 2022 05:46am
- The MOHW (Minister Kwon Deok-cheol) announced at 3 p.m. on the 12th that it will hold a launching meeting of the mid- to long-term strategic planning team for the pharmaceutical industry to establish the "third comprehensive plan for fostering and supporting the pharmaceutical industry." The government shall prepare a five-year comprehensive
- Policy
- Vaccine consultative body launched
- by Kim, Jung-Ju May 13, 2022 05:45am
- Representative vaccine companies in Korea will launch a "Vaccine consultative body" to establish vaccine sovereignty and enhance international competitiveness, and actively cooperate with the aim of strengthening R&D capabilities in the industry and promoting vaccine commercialization. The MOHW (Minister Kwon Deok-cheol) and the Vaccine Pr
- Company
- Lumakras is a new opportunity for lung cancer patients
- by May 13, 2022 05:45am
- "Lumakras is the first-in-class and best-in-class for patients with KRAS G12C mutated non-small cell lung cancer who failed existing treatment. The reliability of drugs has also increased over the past two years with long-term data, and it is expected that they may be used in combination with other drugs such as immuno-cancer drugs in the future
- Company
- LG Chem’s partner enters Phase I trial on its immunotherapy
- by Kim, Jin-Gu May 13, 2022 05:45am
- On the 12th, Cue Biopharma, LG Chem’s partner in developing a cancer immunotherapy, announced it had won FDA approval to initiate Phase 1 clinical trials for ‘CUE-102 .’ LG Chem has exclusive rights to develop and market the candidate in 11 Asian countries including Korea, China, and Japan. With the trial approval, Cue Biopharma wil
- Company
- K-Cab & Fexuclu are quickly targeting the global market
- by Chon, Seung-Hyun May 12, 2022 06:07am
- New drug products developed by domestic pharmaceutical companies with their own technologies are accelerating their targeting in the global market. However, some point out that it is difficult to predict commercial success because there are many variables such as the situation of the local market even if they have reserved to enter the overse
- Policy
- Will Ho-Young Chung be able to enter Cabinet?
- by Lee, Jeong-Hwan May 12, 2022 06:07am
- With the inauguration of the new administration on the 10th, whether the Health and Welfare Minister nominee Ho-Young Chung will be able to enter President Yoon’s Cabinet is now at a crossroads. Industry experts expect that the nominee will be appointed today (12th) after the Minister of Economy and Finance Choo Kyung-ho starts his role
- Company
- 17 are immuno-cancer drugs out of 111 KDDF support projects
- by Kim, Jin-Gu May 12, 2022 06:06am
- Of the 111 KDDF support tasks selected by the government last year, 17 are confirmed to be immuno-cancer drugs. Kim Soon-nam, head of KDDF R&D, who is leading the project, predicted, "In the future, R&D tasks related to immuno-cancer drugs will increase further." Kim Soon-nam, head of the headquarters, attended a session under the theme of
- Policy
- Evusheld will be included in Govnt's supplementary budget
- by Lee, Jeong-Hwan May 12, 2022 06:06am
- The government is setting out to secure a supplementary budget for the introduction of ‘Evusheld (tixagevimab, cilgavimab),’ an antibody combination treatment used to prevent COVID-19 infection in the immunocompromised that see a low effect from vaccinations. With the National Assembly also agreeing on the need to introduce Evusheld, it
